Genome & Company
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The c… Read more
Market Cap & Net Worth: Genome & Company (314130)
Genome & Company (KQ:314130) has a market capitalization of $182.79 Million (₩267.65 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #17223 globally and #566 in its home market, demonstrating a 36.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genome & Company's stock price ₩8610.00 by its total outstanding shares 31085515 (31.09 Million).
Genome & Company Market Cap History: 2020 to 2026
Genome & Company's market capitalization history from 2020 to 2026. Data shows change from $843.91 Million to $182.79 Million (-22.56% CAGR).
Genome & Company Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genome & Company's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Genome & Company's market cap is 0.00 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $368.35 Million | $451.25 Million | -$34.12 Billion | 0.82x | N/A |
| 2022 | $185.23 Million | $14.08 Billion | -$51.84 Billion | 0.01x | N/A |
| 2023 | $132.58 Million | $14.30 Billion | -$47.47 Billion | 0.01x | N/A |
| 2024 | $58.38 Million | $27.74 Billion | -$20.11 Billion | 0.00x | N/A |
Competitor Companies of 314130 by Market Capitalization
Companies near Genome & Company in the global market cap rankings as of March 18, 2026.
Key companies related to Genome & Company by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Genome & Company Historical Marketcap From 2020 to 2026
Between 2020 and today, Genome & Company's market cap moved from $843.91 Million to $ 182.79 Million, with a yearly change of -22.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩182.79 Million | +25.15% |
| 2025 | ₩146.06 Million | +150.18% |
| 2024 | ₩58.38 Million | -55.96% |
| 2023 | ₩132.58 Million | -28.42% |
| 2022 | ₩185.23 Million | -49.71% |
| 2021 | ₩368.35 Million | -56.35% |
| 2020 | ₩843.91 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Genome & Company was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $182.79 Million USD |
| MoneyControl | $182.79 Million USD |
| MarketWatch | $182.79 Million USD |
| marketcap.company | $182.79 Million USD |
| Reuters | $182.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.